Transcription profiling of human hepatitis PBMC C patients treated with Peg-interferon alfa-2b plus ribavirin during the first 10 weeks of treatment

ABSTRACT: Study of PBMC gene expression during the first 10 weeks of therapy with Pegylated-interferon-alfa2b (PegIntronTM) and ribavirin (administered by weight) in HCV patients. This study compared the kinetics of gene expression during the first 10 weeks of therapy with Pegylated-interferon-alfa2b (PegIntronTM) and ribavirin (administered by weight) in HCV patients with the recently completed Virahep C study (9999) in which Peginterferon-alfa2a and ribavirin was administered. RNA was isolated from peripheral blood monocytes from twenty treatment-naïve patients just before treatment (day 0,) and at days 3, 6, 10, 13, 27, 42 and 70 days after treatment. Gene expression at each time was compared to that of day 0 using Affymetrix DNA-micro-arrays. Focusing upon genes that changed at least 1.5-fold a

ORGANISM(S): Homo sapiens

SUBMITTER: Milton Taylor 

PROVIDER: E-GEOD-11342 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress